crocin has been researched along with Schizophrenia* in 3 studies
1 review(s) available for crocin and Schizophrenia
1 trial(s) available for crocin and Schizophrenia
Article | Year |
---|---|
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.
The aim of this study was to assess whether saffron aqueous extract (SAE) or its active constituent, crocin, prevents olanzapine-induced metabolic syndrome (MetS) and insulin resistance in patients with schizophrenia.. 66 patients diagnosed with schizophrenia who were on olanzapine treatment (5-20 mg daily) were randomly allocated to receive a capsule of SAE (n=22; 30 mg daily), crocin (n=22; 30 mg daily) or placebo (n=22) in a 12-week triple-blind trial. Patients were screened not to have MetS at baseline and further assessment was done at weeks 6 and 12. Measurement of fasting blood glucose (FBS) and serum lipids were repeated at weeks 2, 6 and 12. Fasting blood levels of insulin and HbA1c were also measured at baseline and week 12. HOMA-IR and HOMA-β were determined to evaluate insulin resistance.. 61 patients completed the trial and no serious adverse effects were reported. Time-treatment interaction showed a significant difference in FBS in both SAE and crocin groups compared to placebo (p=0.004). In addition, SAE could effectively prevent reaching the criteria of metabolic syndrome (0 patients) compared to crocin (9.1%) and placebo (27.3%) as early as week 6.. SAE could prevent metabolic syndrome compared to crocin and placebo. Furthermore, both SAE and crocin prevented increases in blood glucose during the study. Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Carotenoids; Crocus; Double-Blind Method; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Plant Extracts; Schizophrenia; Waist Circumference | 2014 |
1 other study(ies) available for crocin and Schizophrenia
Article | Year |
---|---|
Crocin alleviates schizophrenia-like symptoms in rats by upregulating silent information regulator-1 and brain derived neurotrophic factor.
In neonatal rats, MK-801 treatments can produce schizophrenia-like symptoms. Crocin is a water soluble carotenoid in Saffron that exerts potent neuroprotective effects. This work aimed to demonstrate the function of crocin in the alleviation of motor and cognitive impairments elicited by MK-801 in a neonatal rodent schizophrenia model, and to illustrate the underlying molecular mechanisms.. Rats were treated with vehicle, MK-801 (1 mg/kg), MK-801 + 25 mg/kg crocin, or MK-801 + 50 mg/kg crocin. Motor learning and coordination, locomotion and exploratory activities, as well as spatial memory were assessed using the rotarod test, pen field test, and the Morris water maze test, respectively. Relative mRNA and protein levels of genes of interest were analyzed using qRT-PCR and Western blot assays, respectively.. In the hippocampus of rats with MK-801-elicited schizophrenia, administration of crocin elevated the expression of silent information regulator-1 (SIRT1) and brain derived neurotrophic factor (BDNF), and relieved the oxidative stress. The learning deficits and motor perturbations caused by MK-801 treatments were also alleviated by the crocin administration.. Collectively, crocin has exerted neuroprotective effects in the rat model of MK-801-elicited schizophrenia, via regulations of SIRT1 and downstream BDNF expression in the hippocampus. Topics: Animals; Brain-Derived Neurotrophic Factor; Carotenoids; Hippocampus; Humans; Maze Learning; Rats; Schizophrenia | 2020 |